Conference attendance fall 2022
September 7, 2022
Commonwealth & 4th Global Wound Conference 2022
October 25, 2022
#STOPWOUNDINFECTIONDAY
October 20, 2022 Articles

Today marks the 2nd annual International Stop Wound Infection Day. This day is about raising awareness of effective identification, prevention and management strategies for wound infection.

To this end, we would like to showcase an in vitro study on how DEBRICHEM® is capable of eradicating all viable cells within the biofilm in just one application. DEBRICHEM® works by withdrawing water from the biofilm, rapidly desiccating, and thus disrupting the biofilm and the pathogens in the wound, ultimately allowing the healing process to start through granulation.

The study, carried out by Mathew Mallone, the current Director of Research for the South West Sydney Limb Preservation and Wound Research Academic Unit, summarises the clinical evidence supporting the efficacy of topical desiccating agent DEBRICHEM® in treating the infection in chronic wounds.

The study was published in the International Journal of Molecular Sciences and can be accessed here.

DEBRICHEM® was evaluated in three in vitro models for its efficacy against biofilms produced by Pseudomonas aeruginosa (ATCC-15442) and Staphylococcus aureus (ATCC-6538). The in vitro biofilm models used were; the MBEC Assay®, Centre for Disease Control (CDC) Biofilm Reactor® and a Semi-solid biofilm model. A 30-s exposure of DEBRICHEM® was used in each model. 

DEBRICHEM® demonstrated complete eradication of viable cells in all models for both strains (p < 0.0001). Imaging with scanning electron microscopy (SEM) was performed where possible. All three models demonstrated complete eradication of viable cells with a 30 s application of a topical wound desiccating agent.

Results:
DEBRICHEM® demonstrated complete eradication of viable cells in all models for both strains (p < 0.0001). Imaging with scanning electron microscopy (SEM) was performed where possible. All three models demonstrated complete eradication of viable cells with a 30 s application of a topical wound desiccating agent.

Results for MBEC Assay® for P. aerurinosa (grey bar) and S. aureus (white bar) reported in CFUmm2. The error bars are demonstrating standard deviation. The *** demonstrates statistical significance of p < 0.0001.
SEM image of P. aeruginosa ATCC-15442 biofilm on a MBEC® peg (A) control at 11,800 magnification and 1 µm and (B) treatment with topical MSA gel solution for 30 s at 6,800 magnification and 1 µm. SEM image of S. aureus ATCC-6538 biofilm on a MBEC® peg (C) control at 11,700 magnification and 1 µm and (D) treatment with topical MSA-DMSO gel solution for 30 s at 11,160 magnification and 1 µm.
SEM image of P. aeruginosa ATCC-15442 biofilm on a polycarbonate coupon (A) untreated control at 15,570 magnification and 1 µm and (B) treatment with topical MSA-DMSO gel solution for 30 s at 1830 magnification and 1 µm. SEM image of S. aureus ATCC-6538 biofilm on a polycarbonate coupon (C) Untreated control at 4910 magnification and 2 µm and (D) treatment with topical MSA-DMSO gel solution for 30 s at 13,900 magnification and 1 µm.

Time is tissue; why wait?
DEBRICHEM® is a disruptive new treatment option to address infection in wounds. The topical agent offers a very effective alternative to surgical debridement, the current standard of care.

Please use our contact form to get in touch with our sales representatives or email info@debx-medical.com.

#STOPWOUNDINFECTIONDAY
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.